Volition’s Nu.Q® Vet Cancer Test now available for pre-order at the point-of-care through Heska

Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis, such as sepsis and COVID-19. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

In this video, we hear from Kevin Wilson, president and chief executive officer of Heska, Dr Tom Butera, chief executive officer of Volition Veterinary, Dr Sue Ettinger, a veterinary cancer specialist, and Dr Heather Wilson-Robles, chief medical officer of Volition Veterinary. Heska’s Nu.Q® Canine Cancer Screen and Monitor Test will operate on Heska’s proprietary Element i+® Immunodiagnostic Analyzer, a point-of-care platform that provides veterinarians with rapid, accurate, low-cost and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes. This is a breakthrough moment for Volition, as it is the first time the Nu.Q® platform is available outside of centralized laboratory testing.